Tel.:
+34 91 736 2385
LOCAL TIME
Contact:
Katarina Gluic
Hours:
Mon-Thu 8:30-17:00 Fri 8:30-15:00
12:35
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
WFH 2014 World Congress
11-15 May 2014 Melbourne
About us
FAQs
Help Line
Personal Area
Homepage
Discussion forum -
WFH 2014 World Congress
Topic -
Inhibitors, Pathogenesis, Prevention and Treatment
If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
Thread / Poster
Author
Replies
Last reply
Effect of vaccinations on inhibitor development in patients with severe hemophilia A
S.M. Hashemi
1
5/7/2014 1:21:00 PM
Experience of Prophylaxis with Activated Prothrombin Complex Concentrate in A Child with Hemophilia B and Inhibitor
Alphan Kupesiz
1
5/6/2014 5:51:00 PM
Observational Immune Tolerance Induction research program (ObsITI) - a multifaceted approach to explore immune tolerance induction
Carmen Escuriola
1
5/5/2014 5:27:00 PM
Low incidence of FVIII inhibitors in patients treated with plasma derived FVIII concentrates and the outcomes of immune tolerance induction with FVIII/vWF concentrates
Tatiana Prigancova
1
4/24/2014 6:24:00 PM
Severe Haemophilia A with high-titre inhibitors and a complicated clinical course
Rajendra Thejpal
1
4/23/2014 11:56:00 PM
Recurrence of Inhibitors after Immune Tolerance Induction: A Retrospective Single-Center Study
Maricel Miguelino
1
4/23/2014 10:12:00 PM
Inhibitor Eradication in Haemophilia: a European Survey
Katharina Holstein
1
4/23/2014 10:00:00 PM
Uptake and timing of inhibitor screening in non-severe haemophilia A: results of a pan-London evaluation
Paul Batty
1
4/23/2014 9:45:00 PM
F8 genotype specific inhibitor risks in Argentine patients with severe HA and particular risk estimation of different mutation types.
Carlos De Brasi
1
4/23/2014 8:37:00 PM
Prospective ADVATE Immune Tolerance Induction Registry (PAIR) Interim Results: Success Rates Continue to Support Published Literature
Amy Shapiro
1
4/23/2014 8:02:00 PM
Transcatheter arterial chemoemboliazation of hepatocellular carcinoma: management of one hemophilia A patient with inhibitor
Takeshi Matsumoto
1
4/23/2014 5:34:00 PM
Bleeding Phenotype And Clinical Management Of Children With Severe Hemophilia A And Inhibitors: A Follow-up Cohort Study.
Maria Elisa Mancuso
1
4/23/2014 3:38:00 PM
Slovenian National data for inhibitor appearance in haemophilia A (HA) patients
majda benedik dolnicar
1
4/23/2014 2:44:00 PM
Inhibitors increase the burden of disease in nonsevere haemophilia A patients - treatment strategies to obtain haemostasis.
Alice van Velzen
1
4/23/2014 1:24:00 PM
Postoperative TGA(Thrombin Generation Assay)monitoring of homeostasis of haemophilia patients with inhibitor
fujihiko minamoto
1
4/23/2014 12:17:00 PM
Early Elimination of Factor VIII Inhibitor by ITI with High Dose Immunoglobulin in Hemophilia A Children
Yoko Mizoguchi
1
4/23/2014 11:41:00 AM
Immune monitoring of FVIII inhibitor development in the Hemophilia Inhibitor PUP Study (HIPS)
Christoph Hofbauer
1
4/23/2014 11:22:00 AM
Elective Orthopaedic Surgery In Patients With Haemophilia And Inhibitors: Still A Big Challenge For Haematologists?
Maria Elisa Mancuso
1
4/23/2014 9:56:00 AM
The Development of Anti-Factor VIII Antibodies Associated with the Change of Serum BAFF Level in Hemophilia A mice
Shin-Nan Cheng
1
4/23/2014 8:25:00 AM
Surgery and Invasive procedure with bypassing agents in hemophilic patients with inhibitors : a single center experience
Young Shil Park
1
4/23/2014 8:12:00 AM
Two consecutive life threatening bleeding episodes in hemophilia A patients with high responding inhibitors
Jung Woo Han
1
4/23/2014 8:05:00 AM
Continues ITI versus prophylaxis with NovoSeven; An immune tolerance induction failure cost analysis model.
Chris Barnes
1
4/23/2014 6:05:00 AM
Pseudotumor causing duodenal fistula and secondary tumor rupture in a hemophilia B patient with high responding inhibitors : case report
Jung Woo Han
1
4/23/2014 5:11:00 AM
Postauthorization safety surveillance study (PASS) of hemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings
Pablo Rendo
1
4/22/2014 8:12:00 PM
Selection and characterization of single-chain variable antibody fragments (scFvs) specific for anti-FVIII antibodies
Kerstin Brettschneider
1
4/22/2014 7:43:00 PM
Experience of prophylactic and on demand treatment of inhibitory form of haemophilia B in children using recombinant activated FVII.
Vladimir Vdovin
1
4/22/2014 4:40:00 PM
Surgical procedures as a risk factor for the inhibitor development in young children with Haemophilia
Rosemarie Shaw-Schwyzer
1
4/22/2014 3:49:00 PM
Comparison of historic on-demand versus prospective on-demand and prophylaxis bleeding episodes in hemophilia A and B patients with inhibitors treated with FEIBA NF
Srilatha Tangada
1
4/22/2014 2:33:00 PM
Does a once weekly prophylaxis with low dose factor VIII in PUPs with haemophilia A decrease the risk of inhibitor development? Results of a survey in centers of the Competence Network Hemorrhagic Diatheses East.
Ralf Knoefler
1
4/22/2014 12:03:00 PM
Successful Management of Orthopedic Surgery in a Patient with Congenital Haemophilia A with Inhibitors from Guatemala, Central America. A Case Report
Marta Julia Lopez
1
4/22/2014 2:54:00 AM
Surveillance for Hemophilia Inhibitors in the United States
Mike Soucie
1
4/21/2014 8:23:00 PM
Natural course of inhibitors in Korean Hemophilia A patients
Eun Jin Choi
1
4/21/2014 7:42:00 AM
Combined (sequential and parallel) therapy with by-passing agents and antifibrinolytics in patients with hemophilia and inhibitor.
Nebojsa Rajic
1
4/20/2014 9:16:00 PM
A Phase III clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in hemophilia patients with inhibitors: hemostatic efficacy and safety
YUICHI SHINKODA
1
4/17/2014 9:16:00 AM
The association of factor VIII genotypes and HLA DRB115, tumor necrosis factor -308A and interleukin -10-1082G alleles on inhibitor development in Thai patients with hemophilia A
Ampaiwan Chuansumrit
1
4/2/2014 2:55:00 AM
FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa.
Tayou Tagny Claude
1
3/23/2014 7:50:00 AM
A Status of Immune Suppression in Hemophilia A with Developed Factor VIII Inhibitors.
Zhenping Chen
1
3/14/2014 8:47:00 AM
Most viewed poster for this congress
Poster:
1
Visits:
2526
Title:
A WEB SITE TO IMPROVE MANAGEMENT OF PATIENTS WITH INHERITED BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT: RESULTS AT 2 YEARS
Authors:
Annarita Tagliaferri ,
Centre:
Centro di Riferimento Regionale per la cura dellEmofilia
Poster most viewed in this topic
Poster:
63
Visits:
314
Title:
A Phase III clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in hemophilia patients with inhibitors: hemostatic efficacy and safety
Authors:
YUICHI SHINKODA ,
Centre:
Kagoshima City Hospital
About us
Terms and Conditions
Special Access
Commercial Web Access
Follow us on: